Technetium Tc-99m Apcitide is a radioconjugate comprised of the small peptide apcitide labeled with the gamma-emitting technetium TC99m (metastable Tc-99).
CAT No: 10-101-157
CAS No:178959-14-3
Synonyms/Alias:Acutect (TN);Technetium Tc 99m apcitide (USP)
Technetium tc 99m Apcitide is a radiolabeled peptide complex that combines the synthetic cyclic peptide apcitide with technetium-99m, a widely utilized gamma-emitting radioisotope. As a member of the radiopharmaceutical peptide category, it is distinguished by its high affinity for the glycoprotein IIb/IIIa receptor on activated platelets. This unique biochemical property underpins its significance in research settings focused on platelet biology, thrombosis, and molecular imaging of vascular processes. The integration of a targeting peptide with a radioisotope enables highly specific binding and detection, making it a valuable tool for investigating platelet-mediated phenomena and advancing the field of nuclear medicine research.
Platelet Aggregation Research: Technetium tc 99m Apcitide serves as a specialized probe for studying platelet activation and aggregation. Its peptide component selectively binds to the glycoprotein IIb/IIIa integrin, a receptor that is upregulated on the surface of activated platelets. By enabling precise tracking of platelet localization and activity, the compound supports detailed investigations into the mechanisms of thrombogenesis, the dynamics of platelet-rich thrombi, and the molecular interactions governing hemostasis. Researchers can utilize this radiolabeled peptide to quantify platelet accumulation in various in vitro and in vivo models, thereby elucidating the cellular and molecular basis of clot formation.
Molecular Imaging Development: The radiotracer properties of technetium-99m, when conjugated to apcitide, provide a robust platform for developing and validating new molecular imaging protocols. In preclinical studies, it can be used to assess the distribution and binding of targeted imaging agents within biological systems. The gamma emission profile of technetium-99m facilitates non-invasive detection using gamma cameras or SPECT imaging, allowing researchers to visualize and quantify the biodistribution of peptide-based tracers. Such capabilities are essential for optimizing imaging agent design, evaluating receptor targeting efficacy, and refining imaging methodologies in the context of vascular biology.
Thrombosis Model Validation: The specific binding affinity of technetium tc 99m-labeled apcitide for activated platelets makes it a powerful tool for validating experimental models of thrombosis. By providing a means to monitor thrombus formation in real time, the compound enables researchers to assess the impact of genetic, pharmacological, or mechanical interventions on platelet-mediated clot development. This application is particularly relevant for benchmarking new antithrombotic agents, characterizing disease models, and investigating the interplay between vascular injury and platelet response in controlled laboratory settings.
Peptide Receptor Targeting Studies: The use of this radiolabeled peptide complex extends to the study of receptor-ligand interactions involving integrin family members. Researchers can employ technetium tc 99m apcitide to probe the specificity and affinity of peptide ligands for glycoprotein IIb/IIIa and related receptors. Such investigations contribute to a deeper understanding of receptor pharmacology, ligand design, and the structural determinants of binding interactions. These insights are instrumental in the rational development of novel peptide-based imaging agents and targeted therapeutics for research use.
Radiolabeling Methodology Optimization: Technetium tc 99m Apcitide provides a practical model system for optimizing radiolabeling techniques involving peptides and small proteins. Its well-characterized chelation chemistry and stable labeling properties allow researchers to refine protocols for technetium-99m conjugation, evaluate labeling efficiency, and assess the stability of radiolabeled complexes under physiological conditions. These methodological advances are critical for the broader application of radiolabeled peptides in molecular imaging, tracer development, and biochemical assay design.
The affinity of various malignant neoplasms including small cell and non-small cell lung cancer for peptide analogs of somatostatin has been well documented. Depreotide is such an analog and can be complexed with technetium-99m (99mTc depreotide) for optimal imaging properties. Using this radiopharmaceutical, solitary pulmonary nodules (SPN) were previously evaluated in a successful phase II/III trial. The results of the larger multicenter phase III study using 99mTc depreotide to differentiate malignant and benign etiologies in SPN are now presented.
A Multicenter Trial with a Somatostatin Analog 99mTc Depreotide in the Evaluation of Solitary Pulmonary Nodules
Technetium Tc-99m disofenin cholescintigraphy (CS) and ultrasonography (US) are two major clinical methods used in differentiating biliary atresia (BA) from neonatal jaundice. To compare the diagnostic utility of these two modalities, 66 patients with neonatal cholestasis (15 BA, 3 choledochal cyst (CC), 32 neonatal hepatitis, 13 prolonged jaundice, 2 total parenteral nutrition, and 1 sepsis) underwent Tc-99m disofenin CS and US. The diagnostic sensitivity, specificity, and accuracy of CS in differentiating BA from other forms of neonatal jaundice was 100%, 87.5%, and 90.5%, respectively, and for US 86.7%, 77.1%, and 79.4%, respectively. Tc-99m disofenin CS after premedication with phenobarbital and cholestyramine is a convenient and reliable method of differentiating BA from neonatal hepatitis, with a diagnostic accuracy superior to that of US. However, US is the initial imaging procedure of choice in patients presenting with jaundice to rule out anatomic anomalies such as CC.
Comparison technetium of Tc-99m disofenin cholescintigraphy with ultrasonography in the differentiation of biliary atresia from other forms of neonatal jaundice
2. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
4. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More